In Brief: Palladone Withdrawn
The Medical Letter review of Palladone (hydromorphone HCl) extended-release capsules (March 14, 2005) warned that a lethal dose could be released if the new formulation was taken with alcohol. Because of that risk, the FDA asked the manufacturer (Purdue) to withdraw the drug from the market (FDA News. July 13, 2005; FDC Reports – “The Pink Sheet” July 18, 2005; 67:3).
This article has been freely provided.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: In Brief: Palladone Withdrawn
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1214
Article Code: 1214c
Date: August 1, 2005
Volume: 47
Page: 61
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1214
Article Code: 1214c
Date: August 1, 2005
Volume: 47
Page: 61
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article.This article is not available for purchase.